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A B S T R A C T
Purpose: Despite the common occurrence of intellectual disability (ID) in people with epilepsy, most
studies of the cost of epilepsy have focussed primarily or exclusively on people without ID. This paper
estimates the costs of supporting people with epilepsy and ID.
Methods: Prospective resource use and outcome data were collected on 91 participants from the east of
England for seven months. Multivariate analysis was used to investigate the relationship between costs
and patient and healthcare provider characteristics.
Results: Mean health care costs relating to epilepsy or ID were £2800 (3500 Euros, 5200 USD) p.a.
Modelling suggests costs are lower for patients with more severe ID (p = 0.014); and higher for patients
managed by a consultant neurologist (p = 0.037).
Discussion: Our ﬁndings support limited evidence from the literature of increased epilepsy costs in
people with ID. Patterns of expenditure suggest clinical variation in the treatment of epilepsy according
to the severity of ID, particularly in the absence of management by a consultant neurologist.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Epilepsy imposes signiﬁcant ﬁnancial costs on individuals,
families and the health care services supporting them. As a
consequence, an understanding of the costs of epilepsy and the
factors inﬂuencing those costs is important for the efﬁcient
delivery of care for people with epilepsy.1 Whilst a number of
studies have examined costs of epilepsy in regions around the
world,2–6 patients with signiﬁcant intellectual disability (ID)
(deﬁned as an IQ of 70 or less) are often excluded. In addition,
psychiatric co-morbidities, which occur at increased rates in those
with ID7 and social support costs for people with epilepsy and ID
are rarely considered in detail.
Nevertheless, ID is relatively common in people with epilepsy,
probably occurring in at least 25%.8,9 Similarly, epilepsy is common
in adults with ID,10 with an overall prevalence of around 26%.11
Epilepsy in adults with ID has a worse prognosis than epilepsy in
the general population, with lower rates of seizure freedom,9 high
rates of multiple antiepileptic drug use,12 and high rates of* Corresponding author at: London School of Hygiene & Tropical Medicine, 15-17,
Tavistock Place, London, WC1H 9SH, UK. Tel.: +44 020 7927 2780;
fax: +44 020 7927 2701.
E-mail address: Mark.Pennington@lshtm.ac.uk (M. Pennington).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.12.012comorbidity13 and mortality.14 All these factors are likely to have
important ﬁnancial implications.
Hence adults with ID represent a distinct and sizeable
proportion of those with epilepsy and one for which costs
associated with delivery of epilepsy care remains under-
researched. Our aim in this paper is to report the health and
social care costs of supporting adults with active epilepsy and ID
living in the community in the UK and to explore determinants of
those costs.
2. Methods
2.1. Study design
This was a prospective study designed to collect data
describing, over seven months, epilepsy; ID; quality of life; and
health and social care utilisation for a group of adults with ID and
epilepsy living in the east of England.
Entry into the study and collection of relevant background data
took place during an initial recruitment visit. Participants then
underwent four subsequent assessments at one, two, six and seven
months. The study aimed to interview the same family member or
paid carer on each occasion, as well as, where feasible, the
participant. Assessments were carried out in participants’ homes
or at the site of day activities in which they were engaged.vier Ltd. All rights reserved.
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In the UK, epilepsy care for adults with ID is generally provided
by some combination of hospital neurology or community ID
health services and primary care. Community ID teams generally
include nurses and psychiatrists with expertise in the management
of epilepsy, and provide services to all adults with an IQ of 70 or
less aged 18–65 years. The areas in our study were also within the
catchment of teaching hospitals which included neurologists with
a special interest in epilepsy and epilepsy specialist nurses. We
sought to recruit 100 adults with ID and active epilepsy whose
epilepsy was managed by a community ID team and 100 whose
epilepsy was managed by a hospital neurology service. These
numbers would have been sufﬁcient to detect a difference of 3
points on the National Seizure Severity Scale with 96% power
(p = 0.05), based on data from a pilot study in Cambridgeshire.
Eligible participants comprised all adults aged between 18 and
65 years with epilepsy and a record of at least one seizure, not
considered to have been non-epileptic, in the six months preceding
the study, with a full scale IQ below 71, living in Cambridgeshire or
Norfolk and known to community ID and/or hospital neurology
services in these counties.
Potentially eligible participants were initially identiﬁed by the
clinicians providing their ongoing epilepsy management. All
potential participants identiﬁed (334) were contacted. Of the
198 responses, 28 were ineligible. The remaining participants were
included in the study provided consent was obtained from those
able to give consent or, in the case of those lacking capacity to
consent, assent was obtained from a carer under the provisions of
the Mental Capacity Act (UK) (2005). The study was approved by
the Cambridgeshire 2 Research Ethics Committee.
2.3. Assessments
At the initial recruitment visit the following information was
collected; clinical details describing severity of ID, the nature of the
epilepsy and its treatment, the prevalence of associated neurolog-
ical and psychopathological comorbidities, accommodation and
demographic information including ethnic origin.
At each of the four subsequent data gathering visits the
following assessments were undertaken (unless frequency is
otherwise speciﬁed); the abbreviated Glasgow Epilepsy Outcome
Scale 35 (GEOS35)15 (completed at ﬁrst and fourth visits only);
Epilepsy and Learning Disabilities Quality of Life Scale (ELD-
QOL);16,17 seizure severity, measured using the seizure severity
scale section of the ELDQOL; Glasgow Depression Scale for people
with a Learning Disability (GDS-LD)18 or the Carer Supplement to
the scale (GDS-CS) for those unable to complete the GDS-LD
themselves; EuroQoL (EQ-5D);19 and a modiﬁed version of the
Client Service Receipt Inventory (CSRI).20 In addition, the primary
carer completed a seizure diary for each participant covering the
seven months of their involvement in the study. Members of the
research team advised carers on how to complete the diary
accurately using a protocol and reviewed it at each visit over the
data collection period, with additional phone calls between visits
to support reliable recording. Clinical details were gathered from
carers and from examination of participants’ clinical records by
members of the research team.
The GEOS35 is a shortened version of the 90 item GEOS90 carer
report.15 Both measures have four subscales measuring carer
‘‘concerns about seizures’’, ‘‘medical treatment’’, ‘‘caring’’ and
‘‘social impact’’. The ELDQOL is a 70 item measure covering seizure
severity, seizure related injury, antiepileptic drug (AED) side
effects, behaviour, mood, physical, cognitive and social function-
ing, communication, overall health and quality of life and family
concerns. The EQ-5D comprises two generic measures of healthstatus: the ‘tariff’ is derived from assessment of functioning in
mobility, self-care, social functioning, pain and mood; the Visual
Analogue Scale (VAS) score is a simple scale of overall health from
zero to 100 (best imaginable health).
The ELDQOL, EQ5D and GEOS35 instruments were scored
according to published protocols. Missing data was imputed
according to scoring protocols, provided sufﬁcient questions had
been completed. The EQ5D tariff scores were based on the UK
general population values,21 which generates scores from minus
0.594 to one (where one is equivalent to full health; zero
represents death; and scores below zero represent health states
rated worse than death).
2.4. Measurement of costs
The study took a societal perspective and attempted to capture
all health and social care input relating to epilepsy and ID including
primary care; inpatient and outpatient care; drug prescriptions;
home adaptations; and support groups and activities for people
with ID. This included valuation of the contribution of family
carers. We modiﬁed the CSRI to make it relevant to people with
epilepsy and ID and to record service use for the previous month
only. The main modiﬁcations were undertaken to collect detailed
data on social care provision, medications and activities relevant to
people with an ID. (The modiﬁed questionnaire is available at
http://www.ciddrg.org.uk/ldrome/.) The questionnaire recorded
the location of activities and contacts with professionals and the
mode of transport for participants where appropriate. Approxi-
mate contact times were recorded. Contact times were combined
with appropriate unit costs (visiting or at place of work) for
professionals and travel costs were added. Unit costs were taken
predominantly from the Unit Costs of Health and Social Care22 and
all costs are in 2008 UK pounds sterling. Outpatient visits were
split into three categories; ID psychiatry, neurology and other.
Inpatient visits were categorised as ID psychiatry, neurology,
specialty-speciﬁc or general medical (long stay) and a cost was
assigned per day. Drug costs were calculated from detailed data on
brand, dose and frequency combined with appropriate costs from
the British National Formulary.23
Valuing time spent by carers is contentious.24,25 We applied a
unit cost equivalent to the average gross hourly wage by category
of employment for hours spent caring by working carers as
recommended by Gold et al.26We applied a value of £7 per hour for
non-working carers, based on the mean unskilled gross wage rate.
To avoid overestimating care costs we classiﬁed caring duties into
four categories: hours directly giving care; hours of leisure activity;
hours supervising; available but sleeping. Hours in each of the
categories were weighted 1, 0.5, 0.2 and 0.1 respectively. The
weights were chosen to reﬂect the likely burden of different caring
activities.
Private sector care providers were reluctant to reveal accom-
modation and placement costs, hence we categorised participants’
placements as residential care; supported living for people with ID;
group homes; or village communities and applied appropriate unit
costs.22
Few cost studies in the literature have utilised a control to
ascertain costs attributable to epilepsy.27 Most include all costs
falling into categories whose most likely cause is epilepsy,3,28,29
and this was the approach we used for health care costs. Costs for
social care were assumed to be entirely attributable to the
combination of ID and epilepsy. Cost data were divided into ﬁve
broad categories to facilitate comparison with other studies:
accommodation costs; social activities; primary health and
community support (including aids and adaptations in the home);
drug costs (relating to epilepsy or ID); and secondary health care
(relating to epilepsy or ID). Primary health and social support
Table 2
Overall costs by category.
n = 90 Mean Median IQR Minimum Maximum
Accommodation £4033 £4918 £3103 £557 £5967
Activities £1041 £877 £1219 0 £4773
Hospital care £75 0 £72 0 £1202
Community care £71 £37 £102 0 £542
Drugs £85 £62 £103 0 £308
Total £5304 £5576 £2548 £1593 £10,114
M. Pennington et al. / Seizure 21 (2012) 205–210 207consisted mainly of health care interventions but included support
by social workers and case management meetings. Home help to
assist with caring tasks was included in accommodation, as was
the estimated cost of informal care. Secondary health care included
inpatient visits; outpatient visits; and any hospital based tests or
investigations related to epilepsy or ID.
2.5. Data analysis
For each participant, mean values were derived for costs and
outcomes measured over multiple time periods. Overall costs were
dominated by accommodation costs. As highlighted earlier our
ability to accurately estimate accommodation costs was limited,
and the tariffs we applied were unlikely to reﬂect the subtle
inﬂuences of participants’ quality of life or epilepsy severity.
Consequently exploration of the impact of patient characteristics
and care pathways on costs was restricted to costs determined
predominantly by the participant’s epilepsy: drug use, and primary
and secondary healthcare. We pre-speciﬁed the inclusion of ﬁve
key variables: age, gender, a measure of ID severity, a measure of
seizure severity, and the assignment of clinician responsible for
epilepsy management. Additional variables were evaluated
according to their signiﬁcance in explaining variability in the cost
data.
The sum of epilepsy related health care costs for each
participant was right skewed as is commonly observed for cost
data.30 Generalised Linear Models (GLM) are preferred for
modelling cost data as they provide increased ﬂexibility in the
choice of distribution; Gamma distributions generally ﬁt cost data
better than Normal distributions.31 However, there are concerns
over the potential robustness of ﬁtting GLM models to small data
sets. Tests of speciﬁcation will be underpowered in a small sample,
and misspeciﬁcation can result in biased estimates of effect.
Consequently we ﬁtted a GLM and an ordinary least squares (OLS)
model to the data. The GLM model was optimised using
appropriate speciﬁcation tests.32–34 The same variables were
examined using an OLS regression with robust standard errors.
3. Results
3.1. Raw data
We gained consent and collected data on a total of 91
participants. For four participants data were available at less than
four time points. Table 1 presents demographic characteristics
describing the participants and mean scores for the ELDQOL,Table 1
Characteristics of the study population.
n Mean Median IQR
Age 91 41.4 42 18
Male 91 51%
Group home 91 63%
ID severitya 91 42%
Status epilepticus in previous year 89 6.7%
Associated neurological morbidity 89 15.7%
Associated psychopathology 89 39.3%
Number of seizure types 82 1.87 2 1
Mean seizure severity scale scoreb 88 21.20 21.9 13.3
Epilepsy duration (years) 79 30.8 31 22
No. of AEDs prescribed 91 2.12 2 2
Psychotropic prescriptions 89 0.3 0 0
ELDQOLb 91 89.5 88 27.3
GEOSb 91 12.70 9.25 11
EQ5D VASb 91 73.3 75 20
EQ5D tariff b 91 0.46 0.438 0.611
a Proportion mild or moderate compared to severe or profound.
b Population statistics for mean score per participant recorded at multiple visits.GEOS35, and EQ5D. Two participants were non-white, reﬂecting
the ethnic composition of Norfolk and Cambridgeshire. Data was
missing on the number of seizure types and age at onset of epilepsy
for some of the participants. The majority of participants lived in
local authority provided group homes or residential settings rather
than with family members. Seven participants lived independent-
ly. Slightly over half the participants had severe or profound ID (IQ
of 35 or less). Most participants had epilepsy since childhood and
the majority were being prescribed more than one AED. Across the
study population the median number of convulsive seizures per
month was 0.7 (range 0–91) and the median number of non-
convulsive seizures per month was 0.6 (range 0–135). Health
Related Quality of Life (HRQoL) measured by the EQ5D tariff was
signiﬁcantly lower than UK norms (0.85 for UK adults);35 EQ5D
VAS scores were also depressed but less strongly.
Table 2 presents the raw monthly cost data. Cost data were
unavailable for one participant. Accommodation costs are the
largest contributor with overall mean costs of just over £4000
(5000 Euros, 7400 USD) a month. The next most signiﬁcant cost
category is Activities. This category included day centres and social
clubs as well as individual interventions such as aromatherapy.
These costs relate predominantly to participants’ ID although
epilepsy is likely to impact on the cost of providing safe
accommodation and activities. The remaining categories (commu-
nity services, hospital services and drug costs) are primarily health
care related to epilepsy. These costs are relatively small; the mean
aggregate costs for hospital care, community care and drugs is
£232 (291 Euros, 429 USD) a month.
A latent class model was used to categorise participants
according to the clinician responsible for their epilepsy manage-
ment based on case note entries and the opinions of primary care
physicians and carers. Forty-two participants were determined to
have their epilepsy primarily managed by a psychiatrist in an ID
team; 36 participants by a neurologist; and 11 participants by a
General Practitioner or by a combination of professionals. We were
unable to assign the management team responsible for epilepsy
care in one participant. Analysis of the raw data revealed that the
mean number of seizure types was 2.06 for participants managed
by a neurologist compared to 1.72 for participants managed by
their ID team and 1.8 for participants managed by their GP. The
prevalence of severe or profound ID was 47% in those managed by a
neurologist compared to 68% in the remaining sample. These
differences were not statistically signiﬁcant at 5%. Table 3 provides
a breakdown of monthly costs arising predominantly from
epilepsy according to clinician managing the participant’s care.
3.2. Analysis of costs
A GLM model of the costs arising primarily from epilepsy was
ﬁtted using a Gamma distribution with a log link for the
explanatory variables. Of the ELDQOL, GEOS-35 and EQ5D
measures of participants’ quality of life, the GEOS-35 ‘concerns
about seizures’ subscale and the EQ5D VAS score proved to be the
best predictors of variation in costs. Initial analysis indicated
similar costs for participants with profound ID and those with
severe ID. In addition the magnitude of cost differences between
Table 4
Regression models of the costs related to epilepsy.
Variable OLS model GLM modela
Robust Robust
Coeff. Std. err. p Value Coeff. Std. err. p Value
Age 2.567842 2.00648 0.205 0.0038044 0.0057164 0.506
Gender 75.3805 40.5996 0.068 0.1343284 0.1344035 0.318
EQ5D VAS score 6.84616 2.658136 0.012 0.025654 0.0056451 0
No. of seizure types 41.55436 23.44151 0.081 0.1104089 0.0700417 0.115
Neurologist led 130.0459 124.6716 0.3 0.471728 0.4384534 0.282
No. of AEDs prescribed 62.9572 22.7093 0.007 0.242757 0.074178 0.001
ID Severity 120.845 35.13072 0.001 0.5272496 0.1251336 0
GEOS concerns about seizures 25.97126 8.730186 0.004 0.1166865 0.0263697 0
Neurologist  ID sev. 92.99328 59.91605 0.125 0.3520732 0.1765226 0.046
County – Cambs. 97.31733 41.30751 0.021 0.4385592 0.1553681 0.005
Constant 600.5831 244.6224 0.017 6.891074 0.7247356 0
AIC = 1103.369 AIC = 1051.393
a Variance function: V(u) = u2; link function: g(u) = ln(u).
Table 3
Costs related to epilepsy according to management of epilepsy treatment.
ID team (n = 42) Neuro (n = 36) GP/other (n = 11) Total (n = 89)
Mean Median Mean Median Mean Median Mean Median
Hospital services £60 £0 £110 £18 £21 £0 £75 £0
Community services £99 £71 £34 £8 £77 £51 £70 £36
Drugs £75 £54 £113 £111 £41 £29 £86 £63
Total £234 £124 £257 £138 £139 £80 £232 £99
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severity was treated as a numerical variable with values one to
three for levels mild/moderate/severe (profound) respectively. We
had a number of indices of seizure severity including the Seizure
Severity subscale of the ELDQOL, the mean number of seizures per
month and the number of different types of seizures. The latter
measure proved to be the most signiﬁcant predictor of costs. The
presence or history of neurological or affective comorbidities, and
the duration of epilepsy were not signiﬁcant predictors of cost.
Neither was the use of rescue medication, but the number of AEDS
prescribed was. Geographic location also proved to be signiﬁcantly
related to costs.
Initial multivariate analysis showed a signiﬁcant difference
between costs for patients managed by a neurologist and patients
managed by their GP (p = 0.036) but no signiﬁcant difference
between costs for patients managed by their ID team or their GP
(p = 0.413). Consequently we combined the groups managed by an
LD team or a GP. The interaction of epilepsy clinician and ID
severity was the only signiﬁcant interaction term. After optimisingTable 5
Impact on costs of patient characteristics and care coordination.
Participant/treatment characteristics OLS model 
Costs Difference 
Neurologist led care £299 £96 
GP/ID team led care £203 
If all sample had mild LD £361 £167 
If all sample had severe LD £194 
GEOS35 ‘seizures’ subscale score 2 £170 £129 
GEOS35 ‘seizures’ subscale score 7 £299 
VAS score of 85 £148 £130 
VAS score of 66 £278 
Cost difference – if all sample received neurologist led care and
If all sample had mild LD £339 £56 
If all sample had severe LD £283 
Cost difference – if all sample received GP/ID team led care and
If all sample had mild LD £376 £242 
If all sample had severe LD £134 
a Conﬁdence intervals constructed from Bootstrapped regressions with 1000 replicathe GLM model we ﬁtted an OLS model to the same explanatory
variables. The models are described in Table 4. Akaike’s Informa-
tion Criteria,36 a measure of model ﬁt, indicated the GLM model
was superior.
The method of recycled predictions37 was used to estimate cost
differences for epilepsy-related care according to a number of
characteristics including neurologist management of epilepsy and
ID severity for both the GLM and OLS models. In this method the
entire sample is assigned a speciﬁc value for a variable of interest,
outcomes are estimated, and then compared with outcomes
arising if the entire sample is assigned the comparator value for the
variable of interest. Predictions from both models were similar
(Table 5). Bootstrapped 95% conﬁdence intervals are presented for
cost differences generated in the GLM model. A reduction in quality
of life as indicated by a change from the upper end to the lower end
of the IQR for either the GEOS35 subscale ‘concerns about seizures’
or the EQ5D VAS scale leads to a signiﬁcant increase in costs. Costs
are signiﬁcantly lower for participants with severe or profound ID
compared to those with mild ID. Costs are signiﬁcantly higherGLM model
Costs Difference 95% CIa p Value
£299 £92 £5 to £178 0.037
£207
£424 £228 £47 to £409 0.014
£196
£170 £134 £50 to £217 0.002
£304
£161 £101 £43 to £160 0.001
£262
£391 £115 £103 to £335 0.301
£276
£441 £287 £48 to £527 0.018
£154
tions.
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costs according to ID severity where patients are managed by a
neurologist due to the strong interaction between ID severity and
neurologist.
4. Discussion
The high health and social care costs of supporting people with
epilepsy and ID and the signiﬁcant prevalence of ID amongst
people with epilepsy indicate that people with ID constitute a large
proportion of health and social care expenditure incurred by
people with epilepsy. Despite this few studies have focussed
primarily or exclusively on the cost of supporting people with
epilepsy and ID.38–40 Our study estimates the total cost to be
around £64,000 (80,000 Euros, 118,000 USD) a year (2008 values).
Three quarters of that expenditure is spent supporting the
accommodation and basic care needs of people with epilepsy
and ID, and a further ﬁfth on day centres, support groups and
activities. Costs falling on social care budgets are far higher than
health care costs.
Our ﬁndings accord with a study of people with severe or
profound ID in a US institution which reported overall annual costs
of 100,000 1997 dollars.38 The additional costs of epilepsy,
excluding treatment provided outside the institution, were
estimated at $2000. Both Morgan et al.39 and Knox40 report
increased hospitalizations in people with epilepsy and ID
compared to people with ID, with Knox estimating that epilepsy
increased Medicaid costs by $7000 (2000 dollars) for people with
only ID. Estimates of the cost of hospital care related to epilepsy in
our study were comparable with published estimates for UK
populations with epilepsy after inﬂation to 2008 values (£540–
£909),27–29 but drug costs and primary care costs in our study were
higher.20,28,29 Overall health care costs were higher than published
estimates for the UK (£729;28 £117729) and Europe (s350–20003)
after inﬂation to 2008 values, indicating epilepsy treatment is
more resource intensive in the presence of ID.
We observed higher costs in patients whose care is coordinated
by a neurologist after controlling for the number of seizure types a
participant had and the number of AEDs prescribed (Table 3). This
ﬁnding may be attributable to unobserved differences in patient
characteristics. However, treatment of refractory epilepsy involves
ﬁnding a balance between exhausting therapeutic options and
providing some stability and predictability for the patient and their
family/carers.13,41 Achieving the best outcome for the individual
requires compromise, with both patient and clinician involved in a
joint process of treatment negotiation and decision-making.41 It is
possible that neurologists are more active in pursuing seizure
control; and that ID teams place a higher emphasis on stability and
avoidance of adverse treatment effects. This may also explain the
observed negative relationship between ID severity and costs; a
relationship primarily noted in participants not managed by a
neurologist. It is plausible that clinical management of epilepsy
was pursued less aggressively in patients with severe and profound
ID not under the care of Neurologists, with the resulting effect of
reducing epilepsy costs. Whilst this variation may be appropriate,
future research investigating the nature and cost-effectiveness of
epilepsy care pathways for adults with ID and epilepsy is
warranted.
The use of the EQ5D in people with restricted ability to
complete questionnaires unaided is limited.42 However, the very
signiﬁcant coefﬁcient on the EQ5D VAS score in our cost models
suggests that this measure is informative in this group. The GEOS-
35 Carer ‘concern about seizures’ subscale was also more strongly
correlated with costs than more objective measures of epilepsy
severity, such as the ELDQOL seizure severity subscale score or the
mean monthly number of seizures, suggesting that future researchshould further explore relationships between carer concerns and
interactions with health services.
Considering the representativeness of the study sample, overall
the group had a mean duration of epilepsy of 31 years, and 70%
were taking more than one antiepileptic drug. A previous survey12
of adults with ID and epilepsy in the same region of England
observed mean duration of epilepsy of 26 years and a monotherapy
rate of 39%, whilst a postal survey of a different region in England
noted 48% receiving antiepileptic drug monotherapy.43 Hence the
study population reported here may have rather more severe
epilepsy than the wider population of adults with ID. This may
have resulted from the eligibility criteria for the study which
required evidence of an epileptic seizure within the preceding six
months. Similarly, although mean number of seizure types was
higher in the neurology than the non-neurology group, despite the
neurology group having a smaller number of severe and profound
ID cases, this difference was non-signiﬁcant and the study’s focus
on people with active epilepsy is likely to have included individuals
across all IQ bands with more refractory epilepsy, associated with a
larger number of seizure types. In addition, compared to the wider
population of adults with ID, the participants of this study were
more likely to have severe or profound ID and to be living in group
homes.44
Clearly the study has a number of limitations. Failure to recruit
the target sample of 200 participants reduced the power of the
study. We had a power of 88% to detect differences in GEOS score of
11 between participants managed by neurology and ID teams
(equivalent to the typical difference in GEOS score for somebody on
antiepileptic drug monotherapy compared to polytherapy). Whilst
data describing participants’ neurological and psychological
disorders were collected we did not collect data on characteristics
such as incontinence and challenging behaviour not considered to
be directly linked to the participant’s epilepsy. However, it is likely
that these characteristics would have inﬂuenced health care costs.
The signiﬁcant inﬂuence of geographic location of care on costs
suggests variation in practice between Cambridgeshire and
Norfolk, two similar, adjoining counties, potentially limiting the
wider generalisability of our ﬁndings to other regions. At the same
time however, the ﬁnding of a geographic effect on costs should be
of interest in itself to those planning services.
The sample achieved necessitated simpliﬁcations in the
modelling of the cost data. Ideally multiple observations on cost
and outcome should be recognised within the model rather than
simply modelling the mean values. In addition, the correlations
between participants in the same county ought to be recognised in
a hierarchical model. We judged the impact of ignoring these
issues to be small given the signiﬁcant risks of unobserved baseline
differences. We also chose to ignore the distinction between
participants managed by their ID team and the small number
managed primarily by their GP given the small sample and the
indication that costs were not signiﬁcantly different. Inferences
drawn from differences in resource use across the participants in
this study must also be tempered by the fact that this was an
observational study. We cannot rule out the possibility that
differences in resource use according to characteristics that appear
signiﬁcant in the model have arisen from a combination of chance
and confounding by unobserved characteristics.
5. Conclusion
Costs on health and social services of supporting people with
epilepsy and ID are high, primarily due to the cost of providing
appropriate accommodation and living support along with
appropriate activities for people with ID. Epilepsy related health
care costs are a small fraction of overall costs. However, this study
suggests that the costs of epilepsy management are higher for
M. Pennington et al. / Seizure 21 (2012) 205–210210people with ID than for the rest of the population. Whilst affective
and neurological comorbidities are relatively common in this
clinical group, they were not found to contribute to differences in
cost estimates for epilepsy related care. The results of the study do
suggest that a signiﬁcant determinant of epilepsy health care
utilisation, as reﬂected in ﬁnancial costs accrued, is a perception by
carers of a worse health state in the person they are caring for. The
unexpected ﬁnding of relatively lower epilepsy related costs in
those with severe and profound ID could relate to less intensive
epilepsy management in these groups, and this together with the
apparent differential ﬁnancial consequences of receiving treat-
ment from neurology as opposed to ID or primary care services
requires further investigation.
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